AbbVie solidifies immunology dominance with US$10.9B cash acquisition of Apogee

USA—AbbVie has agreed to acquire Apogee Therapeutics in an all-cash transaction valued at US$10.9 billion, reinforcing its commitment to the fast-growing immunology market and adding a promising late-stage drug candidate to its pipeline.

The deal is expected to close during the third quarter of 2026, subject to customary regulatory approvals.

Under the agreement, AbbVie will pay US$135.11 per share in cash, representing nearly a 50% premium to Apogee’s closing share price on 18 June.

The acquisition ranks among AbbVie’s largest transactions in recent years and reflects the company’s strategy to expand its next-generation immunology medicines as competition intensifies across the sector.

Zumilokibart takes centre stage

The main attraction for AbbVie is Zumilokibart, Apogee’s lead investigational therapy for inflammatory diseases.

The injectable anti-IL-13 antibody is scheduled to enter a Phase III trial for atopic dermatitis during the second half of 2026.

Unlike many existing treatments, the drug has been engineered to have an extended half-life, which could allow patients to receive maintenance doses only once every three or six months.

Apogee is also advancing the therapy in asthma and eosinophilic oesophagitis, with clinical studies expected to begin over the next two years.

Recent Phase II results and a US$1.3 billion financing collaboration with Blackstone Life Sciences strengthened confidence in the programme and helped position the company for Phase III development before the takeover announcement.

AbbVie believes Zumilokibart could become a best-in-class treatment because of its strong efficacy profile and less frequent dosing schedule.

Analysts have also suggested that the drug could emerge as a significant competitor to leading therapies such as Stelara and Dupixent if clinical development remains on track.

Expanding a growing portfolio

In addition to Zumilokibart, AbbVie will also access Apogee’s immunology pipeline, including APG279, a dual-action therapy for atopic dermatitis that targets IL-13 and OX40 ligand, and APG273, which targets IL-13 and thymic stromal lymphopoietin (TSLP) for asthma and chronic obstructive pulmonary disease (COPD).

The acquisition further strengthens AbbVie’s already dominant immunology franchise, which includes blockbuster medicines Skyrizi, Rinvoq, and Humira.

During the first quarter of 2026, the company generated US$7.29 billion in immunology revenue, highlighting the importance of the therapeutic area to its long-term growth strategy.

Rising interest in immunology

AbbVie’s move comes amid growing industry interest in immunology, one of the most active areas for drug development.

Pharmaceutical companies are increasingly pursuing treatments for inflammatory and autoimmune diseases, encouraged by the commercial success of leading therapies and a rising number of clinical trials in the field.

The acquisition also comes at a strong time for biopharmaceutical dealmaking.

Industry reports show that life sciences mergers and acquisitions exceeded US$65 billion during the first quarter of 2026, reflecting renewed confidence among pharmaceutical companies and investors.

Against that backdrop, AbbVie’s purchase of Apogee underscores the value being placed on innovative immunology assets with the potential to deliver long-term growth.